Inmed announces share consolidation to meet nasdaq listing criteria

Vancouver, british columbia, aug. 23, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces, pursuant to a directors' resolution, inmed will be consolidating all of its issued and outstanding share capital on the basis of one (1) post‐consolidation share for each twenty five (25) pre‐consolidation common shares of the company (the “consolidation”) in order to regain compliance with all of nasdaq's continued listing requirements.
INM Ratings Summary
INM Quant Ranking